Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

masitinib

Biogen Idec building

Biogen to open compassionate use programme for ALS patients with ‘rapidly progressive disease’

Move comes after mounting pressure from patients and campaigners

The ALS patient journey

Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...

Blue Latitude Health

Biogen Idec building

Biogen’s tofersen shows promise in slowing down ALS

Hope for subset of patients with wasting disease

Celgene building

Celgene bulks up pipeline again with $2.1bn Prothena deal

Acquires candidates with potential in Alzheimer’s, ALS and dementia

- PMLiVE

FDA clears new ALS drug Radicava ahead of schedule

MT Pharma’s medicine will soon offer US patients an alternative to Sanofi’s Rilutek

- PMLiVE

AB Science claims first with motor neurone disease therapy

ALS patients on masitnib lived longer without their disease progressing

PatientsLikeMe launches ‘virtual trial’ in ALS

Partners with The Duke ALS Clinic on study of the Soy Peptide Lunasin

- PMLiVE

FDA grants orphan drug status to Treeway’s ALS treatment

Amyotrophic Lateral Sclerosis drug TW001 gainsregulatory benefits

- PMLiVE

AB Science on track for phase III data in Alzheimer’s this year

Trial of masitinib has passed a futility test

Astellas forges $675m muscle alliance with Cytokinetics

Extendscollaboration to include neuromuscular diseases

- PMLiVE

Charity coalition pledges millions for brain disease research

Will invest £30m developing candidates for neurodegenerative conditions

- PMLiVE

Pharma takes the ALS Ice Bucket Challenge

GSK, Evotec and Biogen Idec participate in the social media sensation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links